 | • レポートコード：QYR2104Z4153 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、非アルコール性脂肪性肝疾患治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（酸化防止剤、チアゾリジンジオン、ビグアニド、脂質低下剤、FXR受容体作動薬、その他）、用途別市場規模（病院薬局、調剤薬局、ドラッグストア、オンライン薬局、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・非アルコール性脂肪性肝疾患治療の市場動向 ・企業の競争状況、市場シェア ・非アルコール性脂肪性肝疾患治療の種類別市場規模（酸化防止剤、チアゾリジンジオン、ビグアニド、脂質低下剤、FXR受容体作動薬、その他） ・非アルコール性脂肪性肝疾患治療の用途別市場規模（病院薬局、調剤薬局、ドラッグストア、オンライン薬局、その他） ・非アルコール性脂肪性肝疾患治療の北米市場規模2016-2027（アメリカ、カナダ） ・非アルコール性脂肪性肝疾患治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・非アルコール性脂肪性肝疾患治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・非アルコール性脂肪性肝疾患治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・非アルコール性脂肪性肝疾患治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Roche、Daewoong、Cardax、Merck、Novartis、Gilead Sciences、AstraZeneca、Limerick BioPharma、GW Pharmaceuticals、Allergan、Takeda Pharmaceutical） ・結論 |
Fatty liver disease refers to the accumulation of fat (triglycerides,) in the liver. The liver cell contains fats, but the accumulation of excess fat can be a cause of concern and can lead to liver inflammation known as steatohepatitis. The fatty liver can be caused by alcohol as well as can be non-alcohol. Steatohepatitis can cause liver cirrhosis (fibrosis, scarring, and hardening of the liver). The cause of non-alcoholic fatty liver disease (NAFLD) is unknown. The nonalcoholic fatty liver disease (NAFLD) is one of the most common diseases in the United States. The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising due to rise in prevalence of diabetes and obesity. According to National Health and Nutrition Examination survey, about 20-30% of the general population in the western world suffer from nonalcoholic fatty liver disease (NAFLD). The common symptoms include fatigue, weakness, weight loss and others. The diagnosis of NAFLD requires the combination of different tests such as blood test, ultrasound, CT scan, MRI scan, and liver biopsy. The two types of Nonalcoholic fatty liver disease (NAFLD) includes simple fatty liver and Nonalcoholic Steatohepatitis (NASH). The simple fatty liver is a type of nonalcoholic fatty liver (NAFL), in which fat is deposited, but no inflammation or liver damage is observed. NASH is the inflammation of the liver due to excess fat deposit and can lead to liver damage and disease.
North America is estimated to lead the global nonalcoholic fatty liver disease treatment market due to increase in prevalence of diabetes and cardiovascular diseases in United States. Large number of manufacturers exist in the market, with large number of customer base. Asia Pacific market is also projected to experience high growth in the near future owing to factors such as, increase in healthcare expenditure, rising standard of living, lifestyle changes- attributed to better healthcare and awareness of the cost-effective treatment process with government grants and funding for acceleration in research and development activities.
Market Analysis and Insights: Global Non Alcoholic Fatty Liver Disease Treatment Market
The global Non Alcoholic Fatty Liver Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Non Alcoholic Fatty Liver Disease Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Non Alcoholic Fatty Liver Disease Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Non Alcoholic Fatty Liver Disease Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Non Alcoholic Fatty Liver Disease Treatment market.
Global Non Alcoholic Fatty Liver Disease Treatment Scope and Market Size
Non Alcoholic Fatty Liver Disease Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Non Alcoholic Fatty Liver Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Antioxidants
Thiazolidinedione
Biguanides
Lipid lowering Agents
FXR Receptor Agonist
Others
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Drug Stores
Online Pharmacy
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer
Roche
Daewoong
Cardax
Merck
Novartis
Gilead Sciences
AstraZeneca
Limerick BioPharma
Cardax
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Antioxidants
1.2.3 Thiazolidinedione
1.2.4 Biguanides
1.2.5 Lipid lowering Agents
1.2.6 FXR Receptor Agonist
1.2.7 Others
1.3 Market by Application
1.3.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Drug Stores
1.3.5 Online Pharmacy
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Perspective (2016-2027)
2.2 Non Alcoholic Fatty Liver Disease Treatment Growth Trends by Regions
2.2.1 Non Alcoholic Fatty Liver Disease Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Non Alcoholic Fatty Liver Disease Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Non Alcoholic Fatty Liver Disease Treatment Industry Dynamic
2.3.1 Non Alcoholic Fatty Liver Disease Treatment Market Trends
2.3.2 Non Alcoholic Fatty Liver Disease Treatment Market Drivers
2.3.3 Non Alcoholic Fatty Liver Disease Treatment Market Challenges
2.3.4 Non Alcoholic Fatty Liver Disease Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Revenue
3.1.1 Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Revenue (2016-2021)
3.1.2 Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Non Alcoholic Fatty Liver Disease Treatment Revenue
3.4 Global Non Alcoholic Fatty Liver Disease Treatment Market Concentration Ratio
3.4.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non Alcoholic Fatty Liver Disease Treatment Revenue in 2020
3.5 Non Alcoholic Fatty Liver Disease Treatment Key Players Head office and Area Served
3.6 Key Players Non Alcoholic Fatty Liver Disease Treatment Product Solution and Service
3.7 Date of Enter into Non Alcoholic Fatty Liver Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non Alcoholic Fatty Liver Disease Treatment Breakdown Data by Type
4.1 Global Non Alcoholic Fatty Liver Disease Treatment Historic Market Size by Type (2016-2021)
4.2 Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Type (2022-2027)
5 Non Alcoholic Fatty Liver Disease Treatment Breakdown Data by Application
5.1 Global Non Alcoholic Fatty Liver Disease Treatment Historic Market Size by Application (2016-2021)
5.2 Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Non Alcoholic Fatty Liver Disease Treatment Market Size (2016-2027)
6.2 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type
6.2.1 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2021)
6.2.2 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2022-2027)
6.2.3 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2027)
6.3 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application
6.3.1 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2021)
6.3.2 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2022-2027)
6.3.3 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2027)
6.4 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country
6.4.1 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2016-2021)
6.4.2 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size (2016-2027)
7.2 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Type
7.2.1 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2021)
7.2.2 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2022-2027)
7.2.3 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2027)
7.3 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Application
7.3.1 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2021)
7.3.2 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2022-2027)
7.3.3 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2027)
7.4 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Country
7.4.1 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2016-2021)
7.4.2 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size (2016-2027)
8.2 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Type
8.2.1 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Application
8.3.1 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Region
8.4.1 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size (2016-2027)
9.2 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type
9.2.1 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2027)
9.3 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application
9.3.1 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2027)
9.4 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country
9.4.1 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size (2016-2027)
10.2 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Type
10.2.1 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Application
10.3.1 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Country
10.4.1 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Non Alcoholic Fatty Liver Disease Treatment Introduction
11.1.4 Pfizer Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Non Alcoholic Fatty Liver Disease Treatment Introduction
11.2.4 Roche Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
11.2.5 Roche Recent Development
11.3 Daewoong
11.3.1 Daewoong Company Details
11.3.2 Daewoong Business Overview
11.3.3 Daewoong Non Alcoholic Fatty Liver Disease Treatment Introduction
11.3.4 Daewoong Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
11.3.5 Daewoong Recent Development
11.4 Cardax
11.4.1 Cardax Company Details
11.4.2 Cardax Business Overview
11.4.3 Cardax Non Alcoholic Fatty Liver Disease Treatment Introduction
11.4.4 Cardax Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
11.4.5 Cardax Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Non Alcoholic Fatty Liver Disease Treatment Introduction
11.5.4 Merck Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
11.5.5 Merck Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Non Alcoholic Fatty Liver Disease Treatment Introduction
11.6.4 Novartis Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
11.6.5 Novartis Recent Development
11.7 Gilead Sciences
11.7.1 Gilead Sciences Company Details
11.7.2 Gilead Sciences Business Overview
11.7.3 Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Introduction
11.7.4 Gilead Sciences Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
11.7.5 Gilead Sciences Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Introduction
11.8.4 AstraZeneca Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
11.8.5 AstraZeneca Recent Development
11.9 Limerick BioPharma
11.9.1 Limerick BioPharma Company Details
11.9.2 Limerick BioPharma Business Overview
11.9.3 Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Introduction
11.9.4 Limerick BioPharma Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
11.9.5 Limerick BioPharma Recent Development
11.10 GW Pharmaceuticals
11.10.1 GW Pharmaceuticals Company Details
11.10.2 GW Pharmaceuticals Business Overview
11.10.3 GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Introduction
11.10.4 GW Pharmaceuticals Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
11.10.5 GW Pharmaceuticals Recent Development
11.11 Allergan
11.11.1 Allergan Company Details
11.11.2 Allergan Business Overview
11.11.3 Allergan Non Alcoholic Fatty Liver Disease Treatment Introduction
11.11.4 Allergan Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
11.11.5 Allergan Recent Development
11.12 Takeda Pharmaceutical
11.12.1 Takeda Pharmaceutical Company Details
11.12.2 Takeda Pharmaceutical Business Overview
11.12.3 Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Introduction
11.12.4 Takeda Pharmaceutical Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
11.12.5 Takeda Pharmaceutical Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Non Alcoholic Fatty Liver Disease Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Antioxidants
Table 3. Key Players of Thiazolidinedione
Table 4. Key Players of Biguanides
Table 5. Key Players of Lipid lowering Agents
Table 6. Key Players of FXR Receptor Agonist
Table 7. Key Players of Others
Table 8. Global Non Alcoholic Fatty Liver Disease Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Regions (2016-2021)
Table 12. Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Regions (2022-2027)
Table 14. Non Alcoholic Fatty Liver Disease Treatment Market Trends
Table 15. Non Alcoholic Fatty Liver Disease Treatment Market Drivers
Table 16. Non Alcoholic Fatty Liver Disease Treatment Market Challenges
Table 17. Non Alcoholic Fatty Liver Disease Treatment Market Restraints
Table 18. Global Non Alcoholic Fatty Liver Disease Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Players (2016-2021)
Table 20. Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non Alcoholic Fatty Liver Disease Treatment as of 2020)
Table 21. Ranking of Global Top Non Alcoholic Fatty Liver Disease Treatment Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Non Alcoholic Fatty Liver Disease Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Non Alcoholic Fatty Liver Disease Treatment Product Solution and Service
Table 25. Date of Enter into Non Alcoholic Fatty Liver Disease Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Type (2016-2021)
Table 29. Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Non Alcoholic Fatty Liver Disease Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Application (2016-2021)
Table 33. Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 65. Pfizer Company Details
Table 66. Pfizer Business Overview
Table 67. Pfizer Non Alcoholic Fatty Liver Disease Treatment Product
Table 68. Pfizer Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021) & (US$ Million)
Table 69. Pfizer Recent Development
Table 70. Roche Company Details
Table 71. Roche Business Overview
Table 72. Roche Non Alcoholic Fatty Liver Disease Treatment Product
Table 73. Roche Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021) & (US$ Million)
Table 74. Roche Recent Development
Table 75. Daewoong Company Details
Table 76. Daewoong Business Overview
Table 77. Daewoong Non Alcoholic Fatty Liver Disease Treatment Product
Table 78. Daewoong Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021) & (US$ Million)
Table 79. Daewoong Recent Development
Table 80. Cardax Company Details
Table 81. Cardax Business Overview
Table 82. Cardax Non Alcoholic Fatty Liver Disease Treatment Product
Table 83. Cardax Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021) & (US$ Million)
Table 84. Cardax Recent Development
Table 85. Merck Company Details
Table 86. Merck Business Overview
Table 87. Merck Non Alcoholic Fatty Liver Disease Treatment Product
Table 88. Merck Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021) & (US$ Million)
Table 89. Merck Recent Development
Table 90. Novartis Company Details
Table 91. Novartis Business Overview
Table 92. Novartis Non Alcoholic Fatty Liver Disease Treatment Product
Table 93. Novartis Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021) & (US$ Million)
Table 94. Novartis Recent Development
Table 95. Gilead Sciences Company Details
Table 96. Gilead Sciences Business Overview
Table 97. Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Product
Table 98. Gilead Sciences Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021) & (US$ Million)
Table 99. Gilead Sciences Recent Development
Table 100. AstraZeneca Company Details
Table 101. AstraZeneca Business Overview
Table 102. AstraZeneca Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021) & (US$ Million)
Table 103. AstraZeneca Recent Development
Table 104. Limerick BioPharma Company Details
Table 105. Limerick BioPharma Business Overview
Table 106. Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Product
Table 107. Limerick BioPharma Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021) & (US$ Million)
Table 108. Limerick BioPharma Recent Development
Table 109. GW Pharmaceuticals Company Details
Table 110. GW Pharmaceuticals Business Overview
Table 111. GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Product
Table 112. GW Pharmaceuticals Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021) & (US$ Million)
Table 113. GW Pharmaceuticals Recent Development
Table 114. Allergan Company Details
Table 115. Allergan Business Overview
Table 116. Allergan Non Alcoholic Fatty Liver Disease Treatment Product
Table 117. Allergan Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021) & (US$ Million)
Table 118. Allergan Recent Development
Table 119. Takeda Pharmaceutical Company Details
Table 120. Takeda Pharmaceutical Business Overview
Table 121. Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Product
Table 122. Takeda Pharmaceutical Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021) & (US$ Million)
Table 123. Takeda Pharmaceutical Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Type: 2020 VS 2027
Figure 2. Antioxidants Features
Figure 3. Thiazolidinedione Features
Figure 4. Biguanides Features
Figure 5. Lipid lowering Agents Features
Figure 6. FXR Receptor Agonist Features
Figure 7. Others Features
Figure 8. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Application: 2020 VS 2027
Figure 9. Hospital Pharmacy Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Drug Stores Case Studies
Figure 12. Online Pharmacy Case Studies
Figure 13. Others Case Studies
Figure 14. Non Alcoholic Fatty Liver Disease Treatment Report Years Considered
Figure 15. Global Non Alcoholic Fatty Liver Disease Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 16. Global Non Alcoholic Fatty Liver Disease Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Regions: 2020 VS 2027
Figure 18. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Regions (2022-2027)
Figure 19. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Players in 2020
Figure 20. Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non Alcoholic Fatty Liver Disease Treatment as of 2020
Figure 21. The Top 10 and 5 Players Market Share by Non Alcoholic Fatty Liver Disease Treatment Revenue in 2020
Figure 22. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Type (2016-2021)
Figure 23. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Type (2022-2027)
Figure 24. North America Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. North America Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2016-2027)
Figure 26. North America Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2016-2027)
Figure 27. North America Non Alcoholic Fatty Liver Disease Treatment Market Share by Country (2016-2027)
Figure 28. United States Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Canada Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2016-2027)
Figure 32. Europe Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2016-2027)
Figure 33. Europe Non Alcoholic Fatty Liver Disease Treatment Market Share by Country (2016-2027)
Figure 34. Germany Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. France Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. U.K. Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Italy Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Russia Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Nordic Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2016-2027)
Figure 42. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2016-2027)
Figure 43. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Share by Region (2016-2027)
Figure 44. China Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Japan Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. South Korea Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. India Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Australia Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2016-2027)
Figure 52. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2016-2027)
Figure 53. Latin America Non Alcoholic Fatty Liver Disease Treatment Market Share by Country (2016-2027)
Figure 54. Mexico Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Brazil Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2016-2027)
Figure 58. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2016-2027)
Figure 59. Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Share by Country (2016-2027)
Figure 60. Turkey Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Saudi Arabia Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. UAE Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. Pfizer Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
Figure 64. Roche Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
Figure 65. Daewoong Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
Figure 66. Cardax Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
Figure 67. Merck Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
Figure 68. Novartis Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
Figure 69. Gilead Sciences Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
Figure 70. AstraZeneca Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
Figure 71. Limerick BioPharma Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
Figure 72. GW Pharmaceuticals Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
Figure 73. Allergan Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
Figure 74. Takeda Pharmaceutical Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
世界の非アルコール性脂肪肝疾患治療薬市場規模・現状・予測（2021年-2027年） Nonalcoholic fatty liver disease (NAFLD) is a condition in which excessive fatty accumulation in the hepatocytes. There are two types of NAFLD, namely simple fatty liver and non-alcoholic steatohepatitis. In simple fatty liver, the fat in the liver is very less and there is no inflammation or liver …- 世界の脂肪肝治療市場規模・現状・予測（2021年-2027年） Fatty liver disease is one of the most common liver dysfunction where the triglyceride fat accumulates in liver cells. The major risks associated with fatty liver disease are alcoholic cirrhosis, cardiovascular disorder, metabolic syndrome and biliary cirrhosis among others. Market Analysis and Insi…
- 世界の脂肪肝治療市場規模・現状・予測（2021年-2027年） Fatty liver disease is one of the most common liver dysfunction where the triglyceride fat accumulates in liver cells. The major risks associated with fatty liver disease are alcoholic cirrhosis, cardiovascular disorder, metabolic syndrome and biliary cirrhosis among others. Market Analysis and Insi…
- 世界の脂質代謝疾患治療市場規模・現状・予測（2021年-2027年） Lipid Metabolism Disease Drug is usually used to help lipid metabolism. Market Analysis and Insights: Global Lipid Metabolism Disease Treatment Market The global Lipid Metabolism Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX%…
- 世界の代謝性疾患治療市場規模・現状・予測（2021年-2027年） Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc. Market Analysis and Insights: Global Metabolic Disease Treatment Market The global Metabolic Disease Treatment market size is projected to reach US$ XX million…